R&D News | pharmaphorum

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Jacopo Andreose, Angelini Pharma's chief executive

Angelini taps Sovargen for epilepsy drug in $550m deal

Angelini Pharma has licensed a preclinical-stage mTOR inhibitor from South Korean biotech Sovargen with potential for genetic forms of epilepsy.

News

After internal setbacks, Pfizer buys obesity player Metsera

Pfizer's answer to a string of disappointing projects in obesity R&D? Bolt on a promising pipeline from another developer.

News

Bayer starts pivotal Parkinson's cell therapy trial

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway.

News

Biogen buys CNS delivery specialist Alcyone Therapeutics

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Lila Sciences' $235m first round, and other biofinancings

Recent biotech financings include big rounds for Lila Sciences, Odyssey, and Ollin, with ARTHEx, Dualitas, and YolTech also in on the action.

Roche's oral SERD comes good in 2nd-line breast cancer trial

Angelini taps Sovargen for epilepsy drug in $550m deal

After internal setbacks, Pfizer buys obesity player Metsera

Bayer starts pivotal Parkinson's cell therapy trial

Biogen buys CNS delivery specialist Alcyone Therapeutics

Lila Sciences' $235m first round, and other biofinancings

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

News

Editor's Picks